CRISPR THERAPEUTICS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 53.91 USD | +0.34% |
|
-2.07% | -13.88% |
| 18/04 | Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating | MT |
| 17/04 | Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing | MT |
Chart calendar CRISPR Therapeutics AG
eea2371112e600f84a0a2be.Vh8Az1OhR9O5MBTETTza6L5qsajCkfeLMB29PP9y_DM.JE1vjjDYapTBdXvzDkmyvP8d3-6F07bsVUT_TbVLnl0lbHiMJekPnPdUZw~032bf1daa1b267b81bcc867165e1f4d6
Upcoming events on CRISPR Therapeutics AG
Past events on CRISPR Therapeutics AG
| 10/04/2024 09:15 pm | Needham Healthcare Conference |
| 21/02/2024 11:30 pm | Citi Oncology Leadership Summit |
| 21/02/2024 06:00 pm | Q4 2023 Earnings Release |
| 10/01/2024 03:45 am | JPMorgan Healthcare Conference |
| 11/11/2023 | American Heart Association Scientific Meeting |
| 07/11/2023 02:45 am | Q3 2023 Earnings Release |
| 04/11/2023 09:30 pm | Society for Immunotherapy of Cancer Meeting - Abstract Number: 264 |
| 04/11/2023 09:30 pm | Society for Immunotherapy of Cancer Meeting - Abstract Number: 324 |
| 04/11/2023 09:30 pm | Society for Immunotherapy of Cancer Meeting - Abstract Number: 274 |
| 06/09/2023 08:50 pm | Citi Biopharma Conference |
| 08/08/2023 01:31 am | Q2 2023 Earnings Release |
| 14/06/2023 10:30 pm | Goldman Sachs Global Healthcare Conference |
| 08/06/2023 11:30 am | Annual General Meeting |
| 15/05/2023 09:00 pm | JMP Securities Life Sciences Conference |
| 09/05/2023 11:10 pm | Bank of America Healthcare Conference |
| 09/05/2023 01:31 am | Q1 2023 Earnings Release |
| 20/04/2023 12:30 am | Needham Healthcare Conference |
| 16/04/2023 10:55 pm | American Association for Cancer Research Meeting |
| 06/03/2023 09:00 pm | Cowen Health Care Conference |
| 22/02/2023 11:30 pm | Citi Virtual Oncology Leadership Summit |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 290 255 13.72% | 0,72 2,44 -70.53% | 915 904 1.2% | 1,20 6,71 -82.16% | 371 297 24.87% | 121 |
|
EBITDA Million USD | Released Forecast Spread | 51,5 40,7 26.44% | -345 -332 -3.94% | 391 389 0.59% | -649 -670 3.17% | -203 -292 30.64% | -365 |
|
EBIT Million USD | Released Forecast Spread | 46,7 9,88 373.22% | -354 -337 -5.03% | 374 379 -1.51% | -673 -714 5.7% | -223 -313 28.93% | -483 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 67,3 41,8 61.05% | -348 -329 -5.68% | 380 389 -2.54% | -651 -705 7.7% | -151 -255 40.89% | -464 |
|
Net income Million USD | Released Forecast Spread | 66,9 41,3 61.82% | -349 -330 -5.65% | 378 385 -1.94% | -650 -722 9.99% | -154 -261 41.15% | -454 |
|
EPS USD | Released Forecast Spread | 1,17 0,72 63.64% | -5,29 -5,01 -5.52% | 4,97 4,89 1.54% | -8,36 -9,27 9.82% | -1,94 -3,35 42.17% | -5,49 |
| Announcement Date | 12/02/20 | 16/02/21 | 15/02/22 | 21/02/23 | 21/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 12,9 2,25 472.17% | 0,94 2,45 -61.64% | 0,16 2,20 -92.81% | 0,09 0,54 -82.48% | 0,01 7,37 -99.92% | 100 24,3 311.03% | 70,0 1,62 4221.25% | 0,00 7,96 - | 201 123 63.47% | 25,2 | 11,0 | 29,2 | 47,0 | 38,5 |
|
EBITDA Million USD | Released Forecast Spread | 74,5 -46,9 258.84% | 85,7 | -115 | -117 | -112 | |||||||||
|
EBIT Million USD | Released Forecast Spread | -146 -138 -5.26% | -176 -155 -13.76% | -183 -177 -3.28% | -182 -185 1.41% | -132 -185 28.84% | -64,5 -143 54.93% | -95,2 -177 46.09% | -132 -168 21.13% | 69,6 -16,5 522.72% | -126 | -138 | -126 | -118 | -126 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -144 -132 -8.64% | -176 -150 -16.97% | -180 -171 -5.35% | -175 -177 1.13% | -120 -180 33.36% | -51,7 -133 61.06% | -76,8 -170 54.79% | -112 -156 28.38% | 89,6 -6,65 1446.68% | -127 | -126 | -111 | -103 | -116 |
|
Net income Million USD | Released Forecast Spread | -141 -133 -6.49% | -179 -149 -20.18% | -186 -174 -6.88% | -175 -180 2.81% | -111 -183 39.46% | -53,1 -132 59.66% | -77,7 -169 54% | -112 -157 28.78% | 89,3 -11,4 886.08% | -127 | -127 | -111 | -102 | -116 |
|
EPS USD | Released Forecast Spread | -1,84 -1,75 -5.41% | -2,32 -1,94 -19.66% | -2,40 -2,21 -8.48% | -2,24 -2,26 1.08% | -1,41 -2,31 38.83% | -0,67 -1,64 59.02% | -0,98 -2,10 53.43% | -1,41 -1,98 28.79% | 1,10 -0,23 587.68% | -1,40 | -1,51 | -1,35 | -1,27 | -1,28 |
| Announcement Date | 15/02/22 | 09/05/22 | 08/08/22 | 01/11/22 | 21/02/23 | 08/05/23 | 07/08/23 | 06/11/23 | 21/02/24 | - | - | - | - | - |
More events
Past sector events for CRISPR Therapeutics AG
| Today | GEMPHARMATECH CO., LTD.: Q1 2024 Earnings Release |
| Today | GEMPHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 26/04/2024 10:30 am | BB BIOTECH AG: Q1 2024 Earnings Release |
| 26/04/2024 | BIDE PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 26/04/2024 | PHARMARESOURCES (SHANGHAI) CO., LTD.: Q1 2024 Earnings Release |
| 26/04/2024 | HINOVA PHARMACEUTICALS INC.: Q1 2024 Earnings Release (Projected) |
| 26/04/2024 | BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD.: Q4 2023 Earnings Release |
| 26/04/2024 | CHEMPARTNER PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 25/04/2024 04:30 pm | MORPHIC HOLDING, INC.: Q1 2024 Earnings Release |
| 25/04/2024 11:30 am | PURETECH HEALTH PLC: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- CRSP Stock
- Calendar CRISPR Therapeutics AG
